Blood transfusion experience for cyclosporine/prednisone-treated renal allograft recipients at the University of Texas Medical School at Houston.
Our data indicate that CsA-P-treated primary recipients of cadaveric donor renal allografts as well as haploidentical living-related donor allograft recipients enjoy prolonged, successful patient and graft survivals whether conditioned with pretransplant transfusions or not. The data are important because they reflect clinical results from a single transplant center wherein the recipients have been immunosuppressed for approximately 7 years with little change in protocol. This is an important point since utilizing maximum therapeutic immunosuppressive efficacy will result in prolonged graft and patient survival.
Kerman
R H
RH
Department of Surgery, University of Texas Medical School, Houston.
Van Buren
C T
CT
Lewis
R M
RM
Kahan
B D
BD
D001379:Azathioprine / Q000008:administration & dosage; D001803:Blood Transfusion; D002102:Cadaver; D003524:Cyclosporins / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006082:Graft Enhancement, Immunologic; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D015996:Survival Rate; D013781:Texas / Q000453:epidemiology
D003524:Cyclosporins; D007166:Immunosuppressive Agents; D001379:Azathioprine; D011241:Prednisone